Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iCP-NI in healthy volunteers
NCT05740280Phase 1Terminated
- Sponsor
- Cellivery Therapeutics, Inc.
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of iCP-NI (10 arms), sponsored by Cellivery Therapeutics, Inc. Primary endpoints: Adverse Events at 28 days, Laboratory Abnormalities at 28 days and 3 more. Started Jan 2023; status: terminated.
02
Drugs
iCP-NI
Beyond the preview
Go deeper on NCT05740280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05740280.